Top Highlights
PepGen’s PGN-EDODM1 achieved record 46.5% average splicing correction at 13 weeks in Phase 2.
Four of six patients exceeded 50% correction, with encouraging improvements in muscle function.
Safety was favorable, with mild kidney events; higher-dose results are expected in 2027.
Shares surged 92%; PepGen raised $125 million, while U.S. trial sites remain on hold.
A sharp rise, driven by trial results
PepGen shares surged 92% Tuesday, closing at $4.61, then climbed above $5 in premarket trading Wednesday. The jump followed encouraging results for PGN-EDODM1, the company’s experimental treatment for myotonic dystrophy type 1, or DM1.
In a Phase 2 trial, the 10 mg/kg dose produced an average 46.5% correction in RNA splicing at week 13. RNA splicing is a step in how cells prepare genetic instructions to make proteins. Four of six participants reached at least 50% correction. Analysts called the result a new benchmark, though the small group makes it too early to draw firm conclusions.
Why the science matters in daily life
DM1 is a rare, progressive disease that can impair muscle control and strength. PepGen’s treatment aims to correct the faulty RNA processing caused by repeated sequences in the DMPK gene.
Participants also showed early improvements in muscle relaxation, mobility and grip strength. These changes matter because everyday tasks, from holding objects to moving around, can become difficult for people with DM1. Still, the study does not yet prove that the treatment will deliver lasting benefits or improve quality of life over time.
Promise, with questions still ahead
The 10 mg/kg dose was the lowest tested in the program. PepGen says the higher 12.5 mg/kg group is fully enrolled, with results expected in the first half of 2027. Analysts caution that a modest dose increase may not lead to a larger benefit.
Safety findings were encouraging over 16 weeks, with mild kidney-related events and no reported kidney toxicity. However, the FDA’s partial hold on U.S. trial sites remains in place while the agency reviews earlier animal data. The new results mark a notable shift after disappointing findings from a lower dose, but larger studies and longer follow-up will be needed to show whether the gains are reliable and meaningful for patients.
Discover More Technology Insights
Learn how the Internet of Things (IoT) is transforming everyday life.
Access comprehensive resources on space and science by visiting NASA.
Sci-BioV1
